[go: up one dir, main page]

SG10201408073XA - Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target - Google Patents

Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target

Info

Publication number
SG10201408073XA
SG10201408073XA SG10201408073XA SG10201408073XA SG10201408073XA SG 10201408073X A SG10201408073X A SG 10201408073XA SG 10201408073X A SG10201408073X A SG 10201408073XA SG 10201408073X A SG10201408073X A SG 10201408073XA SG 10201408073X A SG10201408073X A SG 10201408073XA
Authority
SG
Singapore
Prior art keywords
muteins
hngal
lcn2
affinity
given target
Prior art date
Application number
SG10201408073XA
Inventor
Arne Skerra
Michaela Gebauer
Dominik Hinz
Sabine Rauth
Gabriele Matschiner
Martin Huelsmeyer
Original Assignee
Pieris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Ag filed Critical Pieris Ag
Publication of SG10201408073XA publication Critical patent/SG10201408073XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00041—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)

Abstract

Abstract Muteins of human lipocalin 2 (Lcn2, hNGAL) with affinity for a given target The present invention relates to a novel library for the generation of muteins and to novel muteins derived from human lipocalin 2 (Lcn2, hNGAL) and related proteins that bind a given target with detectable affinity. The invention also relates to corresponding nucleic acid molecules encoding such a mute in and to a method for their generation. The invention further relates to a method for producing such a mutein. For example, such muteins may serve to bind and deplete pathological forms of natural biomolecules such as the amyloid beta peptide in Alzheimer's disease or may target the fibronectin extra-domain B, which is associated with tumor neovasculature. Figure for publication: None 66
SG10201408073XA 2009-12-07 2010-12-07 Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target SG10201408073XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26709809P 2009-12-07 2009-12-07

Publications (1)

Publication Number Publication Date
SG10201408073XA true SG10201408073XA (en) 2015-01-29

Family

ID=43597993

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201408073XA SG10201408073XA (en) 2009-12-07 2010-12-07 Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target

Country Status (12)

Country Link
US (3) US9549968B2 (en)
EP (3) EP2990798B1 (en)
JP (5) JP5913120B2 (en)
KR (2) KR101842076B1 (en)
CN (1) CN102770764B (en)
AU (1) AU2010329995B2 (en)
BR (1) BR112012013662B1 (en)
CA (1) CA2779562C (en)
DK (2) DK2510357T3 (en)
RU (2) RU2564125C2 (en)
SG (1) SG10201408073XA (en)
WO (1) WO2011069992A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3230907B2 (en) 1993-09-03 2001-11-19 川崎製鉄株式会社 Method for producing blackened steel sheet excellent in productivity and blackening
RU2564125C2 (en) * 2009-12-07 2015-09-27 Пирис Аг Muteins of human lipocalin 2 (lcn2, hngal) with affinity to certain target
SG187695A1 (en) * 2010-08-16 2013-03-28 Pieris Ag Binding proteins for hepcidin
US9758554B2 (en) 2012-01-31 2017-09-12 Technische Universitaet Muenchen Muteins of α1m lipocalin and method of production therefor
WO2013174783A1 (en) * 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
EP2920202B1 (en) 2012-11-19 2018-08-29 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
EP2925337B1 (en) * 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Mutant ngal proteins and uses thereof
SG10201912019WA (en) 2014-05-22 2020-02-27 Pieris Pharmaceuticals Gmbh Novel specific-binding polypeptides and uses thereof
CA2973640A1 (en) * 2015-01-28 2016-08-04 Rachida Siham Bel Aiba Novel proteins specific for angiogenesis
EP3064507A1 (en) 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
BR112017020434A2 (en) 2015-05-04 2018-06-26 Pieris Pharmaceuticals Gmbh fusion polypeptides, nucleic acid molecule, host cell, method for producing a fusion polypeptide, uses of fusion polypeptide, methods for activating signaling pathways, for costimulating cells, for inducing t lymphocyte proliferation, for directing assembly cd137, to induce a local t-cell response, to induce a local nk cell response, and to induce il-2 production
DK3292137T3 (en) 2015-05-04 2022-10-17 Pieris Pharmaceuticals Gmbh PROTEINS SPECIFIC FOR CD137
MX390894B (en) 2015-05-18 2025-03-21 Pieris Pharmaceuticals Gmbh ANTI-CANCER FUSION POLYPEPTIDE.
KR20180008649A (en) * 2015-05-18 2018-01-24 피어이스 파마슈티컬즈 게엠베하 The mutein of human lipocalin 2 with affinity for glypicane-3 (GPC3)
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules
EA035586B1 (en) 2015-11-30 2020-07-10 Пиерис Острелиа Пти Лтд. Novel anti-angiogenic fusion proteins
TW201725212A (en) 2015-12-10 2017-07-16 第一三共股份有限公司 Novel proteins specific for calcitonin gene-related peptide
EP3485277A1 (en) 2016-07-18 2019-05-22 Philippe Ulsemer Natural microorganisms which are naturally capable of binding toxins and/or toxin receptors
GB201615254D0 (en) 2016-09-08 2016-11-23 Ge Healthcare Bio Sciences Ab Novel Ligand and use thereof
CN107403074B (en) * 2017-06-09 2018-05-29 天津市湖滨盘古基因科学发展有限公司 A kind of detection method and device of mutain
EP3715370A1 (en) 2019-03-28 2020-09-30 Technische Universität München High affinity anticalins directed against human cd98hc
CA3127973A1 (en) * 2019-03-29 2020-10-08 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
DE3779221D1 (en) 1986-08-19 1992-06-25 Genentech Inc DEVICE AND DISPERSION FOR THE INTRAPULMONAL ENTERING OF POLYPEPTIDE GROWTH SUBSTANCES AND CYTOKINS.
JPH01215289A (en) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk Production of normal human serum albumin a through gene recombination
FR2649991B2 (en) 1988-08-05 1994-03-04 Rhone Poulenc Sante USE OF STABLE DERIVATIVES OF PLASMID PKD1 FOR THE EXPRESSION AND SECRETION OF HETEROLOGOUS PROTEINS IN YEASTS OF THE GENUS KLUYVEROMYCES
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
ES2245780T3 (en) 1994-05-18 2006-01-16 Nektar Therapeutics METHODS AND COMPOSITIONS FOR THE FORMULATION OF INTERFERONS AS A DRY POWDER.
DE4417598A1 (en) 1994-05-19 1995-12-14 Max Planck Gesellschaft Use of the tetracycline promoter for the stringently regulated production of recombinant proteins in prokaryotic cells
AU5132096A (en) 1995-01-30 1996-08-21 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19641876B4 (en) 1996-10-10 2011-09-29 Iba Gmbh streptavidin muteins
WO1998016873A1 (en) 1996-10-14 1998-04-23 Firm Forsat Ltd. Method for preparing dispersions of chromogenic components
JP2001512668A (en) 1997-08-06 2001-08-28 ザイモジェネティクス，インコーポレイティド Lipocalin homolog
DE19742706B4 (en) 1997-09-26 2013-07-25 Pieris Proteolab Ag lipocalin muteins
US20140080177A1 (en) 1997-09-26 2014-03-20 Pieris Ag Anticalins
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
KR20010052622A (en) 1998-06-08 2001-06-25 프리돌린 클라우스너, 롤란드 비. 보레르 Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
CA2343917A1 (en) 1998-10-19 2000-04-27 Ariad Gene Therapeutics, Inc. Materials and methods involving conditional retention domains
RU2260599C2 (en) * 1999-03-04 2005-09-20 Прикис Фамэсьютикэлс Инкопэрейтид MODULATING AGENT FOR AGGREGATION OF β-AMYLOID FOR AGGREGATION INHIBITION OF NATURAL β-AMYLOID OR FOR TREATMENT OF SUBJECT WITH DISORDER ASSOCIATED WITH β-AMYLOIDOSIS, PHARMACEUTICAL COMPOSITION AND METHOD FOR DETECTION OF NATURAL β-AMYLOID PEPTIDE IN BIOLOGICAL SAMPLE
DE19926068C1 (en) 1999-06-08 2001-01-11 Arne Skerra Muteins of the bilin binding protein
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
AU2001298053A1 (en) 2001-09-27 2003-04-14 Pieris Proteolab Ag Muteins of apolipoprotein D
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
AU2003275958A1 (en) * 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
JP2007284351A (en) * 2004-07-27 2007-11-01 Osaka Bioscience Institute Substances that suppress amyloid protein aggregation and their actions
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
WO2007038619A2 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
CN101516907B (en) * 2006-08-01 2015-08-26 皮里斯股份公司 Mutant protein of tear lipocalin and method for obtaining same
JP5608368B2 (en) * 2006-08-01 2014-10-15 ピエリス アーゲー Tear lipocalin mutein and method for obtaining the same
CA2702611A1 (en) * 2007-10-19 2009-04-23 Abbott Laboratories Immunoassays and kits for the detection of ngal
US8420051B2 (en) 2008-06-24 2013-04-16 Technische Universitaet Meunchen Muteins of hNGAL and related proteins with affinity for a given target
RU2564125C2 (en) * 2009-12-07 2015-09-27 Пирис Аг Muteins of human lipocalin 2 (lcn2, hngal) with affinity to certain target
SG187695A1 (en) 2010-08-16 2013-03-28 Pieris Ag Binding proteins for hepcidin
US9260492B2 (en) 2010-11-15 2016-02-16 Pieris Ag Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3)
EP2920202B1 (en) * 2012-11-19 2018-08-29 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
CA2973640A1 (en) 2015-01-28 2016-08-04 Rachida Siham Bel Aiba Novel proteins specific for angiogenesis
CA2976687A1 (en) 2015-02-18 2016-08-25 Sanofi Novel proteins specific for pyoverdine and pyochelin
DK3292137T3 (en) 2015-05-04 2022-10-17 Pieris Pharmaceuticals Gmbh PROTEINS SPECIFIC FOR CD137
KR20180008649A (en) 2015-05-18 2018-01-24 피어이스 파마슈티컬즈 게엠베하 The mutein of human lipocalin 2 with affinity for glypicane-3 (GPC3)
TW201725212A (en) 2015-12-10 2017-07-16 第一三共股份有限公司 Novel proteins specific for calcitonin gene-related peptide

Also Published As

Publication number Publication date
US20130079286A1 (en) 2013-03-28
US20170114109A1 (en) 2017-04-27
JP2013512683A (en) 2013-04-18
CN102770764B (en) 2016-04-20
EP3660510A3 (en) 2020-07-08
US9549968B2 (en) 2017-01-24
KR101842076B1 (en) 2018-03-27
EP2990798A1 (en) 2016-03-02
JP2018148914A (en) 2018-09-27
EP2990798B1 (en) 2019-09-25
RU2564125C2 (en) 2015-09-27
AU2010329995A1 (en) 2012-05-10
JP2022160410A (en) 2022-10-19
AU2010329995B2 (en) 2015-09-17
JP5913120B2 (en) 2016-05-11
CA2779562A1 (en) 2011-06-16
US10618941B2 (en) 2020-04-14
DK2990798T3 (en) 2019-12-02
DK2510357T3 (en) 2016-07-18
JP7482544B2 (en) 2024-05-14
EP2510357A2 (en) 2012-10-17
RU2707126C2 (en) 2019-11-22
CA2779562C (en) 2019-12-31
JP6346159B2 (en) 2018-06-20
KR20120117815A (en) 2012-10-24
RU2015137158A (en) 2018-12-25
JP2016105709A (en) 2016-06-16
WO2011069992A2 (en) 2011-06-16
KR20180031081A (en) 2018-03-27
JP2021006024A (en) 2021-01-21
BR112012013662B1 (en) 2022-08-02
CN102770764A (en) 2012-11-07
EP2510357B1 (en) 2016-03-30
RU2012128586A (en) 2014-01-20
KR101974044B1 (en) 2019-04-30
US11827681B2 (en) 2023-11-28
RU2015137158A3 (en) 2018-12-25
BR112012013662A2 (en) 2020-11-03
WO2011069992A3 (en) 2011-08-11
US20200308237A1 (en) 2020-10-01
EP3660510A2 (en) 2020-06-03

Similar Documents

Publication Publication Date Title
SG10201408073XA (en) Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
MX2010004915A (en) Antibodies to gdf8 as uses thereof.
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
EA201690946A1 (en) FGF21 MUTANTS AND THEIR APPLICATIONS
EA201171220A1 (en) FGF21 MUTANTS AND THEIR APPLICATIONS
UA97473C2 (en) Normal;heading 1;heading 2;heading 3;ANTIBODIES DIRECTED TO HER-3 AND USES THEREOF
MX2010008570A (en) Alpha 5 - beta 1 antibodies and their uses.
UA107490C2 (en) TNF-α-Binding Protein
MX2009002816A (en) Albumin fusion proteins.
MX2009005189A (en) Human monoclonal antibodies to btla and methods of use.
TNSN08064A1 (en) Albumin fusion proteins
UA113609C2 (en) ANTIGENCY BINDING PROTEIN Binding HUMAN IL-23
EA201270713A1 (en) PROTEINS BASED ON FIBRONECTIN WITH FRAMED DOMAINS THAT BIND IL-23
EA200901436A1 (en) Antigen-binding proteins that bind PAR-2
MY177065A (en) 4-1bb binding molecules
MX2009002418A (en) Antibodies to bone morphogenic proteins and receptors therefor and methods for their use.
WO2006089230A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
EA201990619A1 (en) FGF21 MUTANTS AND THEIR APPLICATION
EA200800953A1 (en) HUMAN MONOCLONAL ANTIBODIES TO CD70
MX2008009886A (en) Antibodies that bind par-2.
BR112012018914A2 (en) "humanized antibody, antigen binding protein, nucleic acid molecule, expression vector, recombinant host cell, antibody or antigen binding protein, methods for producing an antigen binding protein and for treating a subject affected by an autoimmune or inflammatory disease, and, pharmaceutical composition. "
UA96139C2 (en) Anti-neuropilin-1 (nrp1) antibody
EA201290849A1 (en) OPTIMIZED MONOCLONAL ANTIBODIES AGAINST THE TISSUE FACTOR INHIBITOR (TFPI)
EA201290069A1 (en) MODIFIED POLYPEPTIDES OF FACTOR IX AND THEIR APPLICATION
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof